

Special Issue

Imaging Cancer Metabolism

Message from the Guest Editor

Dysregulated tumor metabolism, following hypoxia and poor perfusion, is a recognized hallmark of cancer. Beyond that, upregulated glycolysis, amino acid and lipid metabolism undergo similar reprogramming, providing additional opportunities not only for early detection and diagnosis, but also for targeted therapies that modify cancer metabolism. This Special Issue aims to cover the most advanced imaging techniques that can provide new insights into cancer biology and metabolism. We welcome submissions from the diverse field of imaging, such as PET, MRI (including chemical exchange saturation transfer – CEST MRI and hyperpolarized MR), MRS, Optical Imaging, Photoacoustic Imaging, and Electron Paramagnetic Imaging. We focus on advances in technologies/methods and in development of new dedicated tracers/radioligands or contrast agents that can assess metabolic pathways or metabolites and related alterations (tumor acidosis/pH imaging). In addition, researchers in the field are invited to contribute their recent findings in both the detection and imaging of metabolic substrates and in monitoring response to therapy, covering preclinical and clinical studies.

Guest Editor

Dr. Dario Livio Longo

Institute of Biostructures and Bioimaging (IBB), National Research Council of Italy (CNR) Torino, Italy

Deadline for manuscript submissions

closed (20 August 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/49308

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)